Transcend Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Transcend Therapeutics, Inc. - overview
Established
2021
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2021 by Chairman Kevin Ryan, CEO Blake Mandell, and Chief Scientific Advisor Benjamin Kelmendi, Transcend Therapeutics, Inc. operates as a psychoactive medicine's provider for neuropsychiatric disease. In Q2 2026, Otsuka Pharmaceutical Co. , Ltd.
, a portfolio company of AN Ventures acquired Transcend Therapeutics, Inc. from Alumni Ventures Group, FJ Labs, Alpha Wave Global, Emerald Development Managers, Global Founders Capital, and Integrated. vc for USD 1. 2 billion.
Transcend Therapeutics develops psychoactive drugs for patients suffering from post-traumatic stress disorder (PTSD) and depression. The company provides a compound known as TSND-201, which is medicine for short-acting and mild psychological treatment for PTSD. The firm serves industries such as biotechnology, Pharmacy, healthcare, and hospital. The acquisition aims to support strengthens Otsuka Pharmaceutical Co.
, Ltd. ’s build its psychiatric services and solutions by integrating Transcend Therapeutics, Inc. capabilities.
Current Investors
Alumni Ventures Group, FJ Labs, Otsuka Pharmaceutical Co., Ltd.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Mental Health Services
Website
www.transcendtherapeutics.com
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Transcend Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.